

Citations

1. Genazzani AD, Stomati M, Bernardi F et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. *Fertil Steril* 2003;80:1495-1501.
2. Schmidt PJ, Daly RC, Bloch M et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. *Arch Gen Psychiatry* 2005;62:154-162.
3. Nair KS, Rizza RA, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. *N Engl J Med* 2006;355:1647-1659.
4. Kroboth PD, Salek FS, Stone RA et al. Alprazolam increases dehydroepiandrosterone concentrations. *J Clin Psychopharmacol* 1999;19:114-124.
5. Frye RF, Kroboth PD, Folan MM et al. Effect of DHEA on CYP3A-mediated metabolism of triazolam. *Clin Pharmacol Ther* 2000;67:109 (Abstract PI-182).
6. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. *J Clin Endocrinol Metab* 1993;76:1464-1469.
7. Porsova-Dutoit I, Sulcova J, Starka L. Do DHEA/DHEAS play a protective role in coronary heart disease? *Physiol Res* 2000;49 Suppl 1:S43-S56.
8. Casson PR, Faquin LC, Stentz FB et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. *Fertil Steril* 1995;63:1027-1031.
9. Kawano H, Yasue H, Kitagawa A et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. *J Clin Endocrinol Metab* 2003;88:3190-3195.
10. Nilsson T, Mellbring G, Damber JE. Relationships between tissue plasminogen activator, steroid hormones and deep vein thrombosis. *Acta Chir Scand* 1985;151:515-519.
11. Geisler J, Engelsens BA, Berntsen H et al. Differential effect of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. *J Endocrinol* 1997;153:307-312.
12. Rattya J, Turkka J, Pakarinen AJ et al. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. *Neurology* 2001;56:31-36.
13. Nakamura H, Torimoto N, Ishii I et al. CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. *Drug Metab Dispos* 2003;31:432-438.
14. Bauer J, Blumenthal S, Reuber M, Stoffel-Wagner B. Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. *Neurology* 2004;62:243-246.
15. Isojarvi JJ, Pakarinen AJ, Rautio A et al. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. *Eur J Clin Pharmacol* 1995;47:461-464.
16. Howard JS 3rd. Severe psychosis and the adrenal androgens. *Integr Physiol Behav Sci* 1992;27:209-215.
17. Markowitz JS, Carson WH, Jackson CW. Possible dihydroepiandrosterone-induced mania. *Biol Psychiatry* 1999;45:241-242.
18. Dean CE. Prasterone (DHEA) and mania. *Ann Pharmacother* 2000;34:1419-1422.
19. Stomati M, Rubino S, Spinetti A et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. *Gynecol Endocrinol* 1999;13:15-25.
20. Judd HL, McPherson RA, Rakoff JS, Yen SS. Correlation of the effects of dexamethasone administration on urinary 17-ketosteroid and serum androgen levels in patients with hirsutism. *Am J Obstet Gynecol* 1977;128:408-417.
21. Smith BJ, Buxton JR, Dickeson J, Heller RF. Does beclomethasone dipropionate suppress dehydroepiandrosterone sulphate in postmenopausal women? *Aust N Z J Med* 1994;24:396-401.
22. Riedel M, Wiese A, Schurmeyer TH, Brabant G. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. *Exp Clin Endocrinol* 1993;101:106-111.
23. Rosen T, Wiren L, Wilhelmssen L et al. Decreased psychological well-being in adult patients with growth hormone deficiency. *Clin Endocrinol (Oxf)* 1994;40:111-116.
24. Morales AJ, Nolan JJ, Nelson JC, Yen SS. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Clin Endocrinol Metab* 1994;78:1360-1367.
25. Robinson B, Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids? *Rheumatology (Oxford)* 1999;38:488-495.
26. Nadeau J, Toogood JH, Crilly RG, Wells GA. Suppression of androgen production by the antiasthmatic inhaled steroid, budesonide. *J Allergy Clin Immunol* 1986;77:150.

Citations and Reference Literature: DHEA

27. Toogood JH, Crilly RG, Jones G et al. Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis. *Am Rev Respir Dis* 1988;138:57-61.
28. Zietz B, Reber T, Oertel M et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. *J Rheumatol* 2000;27:911-918.
29. Cutolo M, Sulli A, Pizzorni C et al. Cortisol, dehydroepiandrosterone sulfate, and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy. *Ann NY Acad Sci* 2002;966:91-96.
30. Straub RH, Scholmerich J, Zietz B. Replacement therapy with DHEA plus corticosteroids in patients with chronic inflammatory diseases: substitutes of adrenal and sex hormones. *Z Rheumatol* 2000;59 Suppl 2:II/108-118.
- 30a. Meno-Tetang GM, Blum RA, Schwartz KE, Jusko WJ. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. *J Clin Pharmacol* 2001;41(11):1195-1205.
31. Petri MA, Lahita RG, van Vollenhoven RF et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2002;46:1820-1829.
32. Nordmark G. Effects of DHEA on quality of life in glucocorticoid treated women with SLE. (Abstract OP0180). European Congress of Rheumatology. Berlin; 2004.
33. Nordmark G, Bengtsson C, Larsson A et al. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus. *Autoimmunity* 2005;38:531-540.
34. Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. *Crit Care Med* 1997;25:1207-1214.
35. Mortola JF, Yen SS. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. *J Clin Endocrinol Metab* 1990;71:696-704.
36. Mahesh VB, Greenblatt RB. The in vivo conversion of dehydroepiandrosterone and androstenedione to testosterone in the human. *Acta Endocrinol* 1962;19:113-119.
37. Bosy TZ, Moore KA, Poklis A. The effect of oral dehydroepiandrosterone (DHEA) on the urine testosterone/epitestosterone (T/E) ratio in human male volunteers. *J Anal Toxicol* 1998;22:455-459.
38. Bowers LD. Oral dehydroepiandrosterone supplementation can increase the testosterone/epitestosterone ratio. *Clin Chem* 1999;45:295-297.
39. Morales AJ, Haubrich RH, Hwang JY et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. *Clin Endocrinol (Oxf)* 1998;49:421-432.
40. Wolfe OT, Neumann O, Hellhammer DH et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab* 1997;82:2363-2367.
41. Burd ID, Bachmann GA. Androgen replacement in menopause. *Curr Womens Health Rep* 2001;1:202-205.
42. Zofkova I, Zajickova K, Hill M, Horinek A. Apolipoprotein E gene determines serum testosterone and dehydroepiandrosterone levels in postmenopausal women. *Eur J Endocrinol* 2002;147:503-506.
43. Klann RC, Holbrook CT, Nyce JW. Chemotherapy of murine colorectal carcinoma with cisplatin and cisplatin plus 3'-deoxy-3'-azidothymidine. *Anticancer Res* 1992;12:781-787.
44. Yang JY, Schwartz A, Henderson EE. Inhibition of 3'-azido-3'-deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro. *Biochem Biophys Res Commun* 1994;201:1424-1432.
45. Rabkin JG, McElhiney MC, Rabkin R et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. *Am J Psychiatry* 2006;163:59-66.
46. Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. *J Clin Pharmacol* 2002;42:247-266.
47. Lavalley B, Provost PR, Kahwash Z et al. Effect of insulin on serum levels of dehydroepiandrosterone metabolites in men. *Clin Endocrinol (Oxf)* 1997;46:93-100.
48. Nestler JE, Beer NA, Jakubowicz DJ, Beer RM. Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. *J Clin Endocrinol Metab* 1994;78:549-554.

Reference Literature

- [No author listed.] Dietary supplements in the elderly. Bethesda, MD: NIH Office of Dietary Supplements; 2003.
- Acacio BD, Stanczyk FZ, Mullin P, et al. Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term daily oral administration to healthy young men. *Fertil Steril* 2004;81(3):595-604.

Citations and Reference Literature: DHEA

- Achermann JC, Silverman BL. Dehydroepiandrosterone replacement for patients with adrenal insufficiency. *Lancet* 2001;357(9266):1381-1382.
- Allolio B, Arlt W. DHEA treatment: myth or reality? *Trends Endocrinol Metab* 2002;13(7):288-294. (Review)
- Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. *J Clin Endocrinol Metab* 2001;86(10):4686-4692.
- Arlt W. Dehydroepiandrosterone replacement therapy. *Semin Reprod Med* 2004;22(4):379-388. (Review)
- Arlt W. Quality of life in Addison's disease: the case for DHEA replacement. *Clin Endocrinol (Oxf)* 2002;56(5):573-574.
- Arlt W, Callies F, Koehler I, et al. Dehydroepiandrosterone supplementation in healthy men with an age-related decline of dehydroepiandrosterone secretion. *J Clin Endocrinol Metab* 2001;86(10):4686-4692.
- Barrett-Connor E, Friedlander NJ, Khaw KT. Dehydroepiandrosterone sulfate and breast cancer risk. *Cancer Res* 1990;50:6571-6574.
- Bates GW Jr, Egerman RS, Umstot ES, et al. Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. *Ann N Y Acad Sci* 1995;774:291-293.
- Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge study to a sociobiomedical issue. *Proc Natl Acad Sci U S A* 2000;97(8):4279-4284.
- Beer NA, Jakubowicz DJ, Beer RM, et al. Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women. *J Clin Endocrinol Metab* 1994;79(4):1077-1081.
- Bernstein L, Ross RK, Pike MC, et al. Hormone levels in older women: a study of post-menopausal breast cancer patients and healthy population controls. *Br J Cancer* 1990;61:298-302.
- Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer. *J Natl Cancer Inst* 1996;88:291-296.
- Binello E, Gordon CM. Clinical uses and misuses of dehydroepiandrosterone. *Curr Opin Pharmacol* 2003;3(6):635-641. (Review)
- Blauer KL, Poth M, Rogers WM, et al. Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. *Endocrinology* 1991;129(6):3174-3179.
- Bosy TZ, Moore KA, Poklis A. The effect of oral dehydroepiandrosterone on the urine testosterone/epitestosterone ration (T/E) in human male volunteers. *J Anal Toxicol* 1998;22:455-459.
- Bowers LD. Oral dehydroepiandrosterone supplementation can increase the testosterone/epitestosterone ratio. *Clin Chem* 1999;45:295-297.
- Burd ID, Bachmann GA. Androgen replacement in menopause. *Curr Womens Health Rep* 2001;1(3):202-205. (Review)
- Buster JE, Casson PR, Straughn AB, et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionality studies. *Am J Obstet Gynecol* 1992;166:1163-1168.
- Calabrese VP, Isaacs ER, Regelson W. Dehydroepiandrosterone in multiple sclerosis: positive effects on the fatigue syndrome in a non-randomized study. In: Kalimi M, Regelson W, eds. *The biologic role of dehydroepiandrosterone (DHEA)*. New York: Walter de Gruyter; 1990:95-100.
- Callies F, Fassnacht M, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency: effects on body composition, serum leptin, bone turnover, and exercise capacity. *J Clin Endocrinol Metab* 2001;86(5):1968-1972.
- Carmina E, Ferin M, Gonzalez F, Lobo RA. Evidence that insulin and androgens may participate in the regulation of serum leptin levels in women. *Fertil Steril* 1999;72(5):926-931. PMID: 10561001.
- Casson PR, Elkind-Hirsch KE, Buster JE, et al. Effect of postmenopausal estrogen replacement on circulating androgens. *Obstet Gynecol* 1997;90(6):995-998.
- Casson PR, Faguin LC, Stentz FB, et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. *Fertil Steril* 1995;63(5):1027-1031.
- Chang DM, Chu SJ, Chen HC, et al. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus. *Ann Rheum Dis* 2004;63(12):1623-1626.
- Chen CC, Parker CR Jr. Adrenal androgens and the immune system. *Semin Reprod Med* 2004;22(4):369-377. (Review)
- Cizza G, Dorn LD, Lotsikas A, et al. Circulating plasma leptin and IGF-1 levels in girls with premature adrenarche: potential implications of a preliminary study. *Horm Metab Res* 2001;33(3):138-143.
- Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. *J Clin Endocrinol Metab* 1995;80(7):2057-2062.
- Davidson M, Marwah A, Sawchuk RJ, et al. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. *Clin Invest Med* 2000;23(5):300-310.
- Davidson MH, Weeks CE, Lardy H, et al. Safety and Endocrine effects of 3-acetyl-7-oxo DHEA (7-keto DHEA). *FASEB J* 1998; (Abstracts Part II):4429.

Citations and Reference Literature: DHEA

- Davis SR, Davison SL, Donath S, et al. Circulating androgen levels and self-reported sexual function in women. *JAMA* 2005;294:91-96.
- De Lorenzo A, Lello S, Andreoli A, et al. Body composition and androgen pattern in the early period of postmenopause. *Gynecol Endocrinol* 1998;12(3):171-177.
- Derksen RH. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus. *Semin Arthritis Rheum* 1998;27(6):335-347. (Review)
- Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 1996;5:533-539.
- Fava M, Rosenbaum JF, MacLaughlin RA, et al. Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. *Psychiatry Res* 1989;28(3):345-350.
- Frye RF, Kroboth PD, Kroboth FJ, et al. Sex differences in the pharmacokinetics of dehydroepiandrosterone (DHEA) after single- and multiple-dose administration in healthy older adults. *J Clin Pharmacol* 2000;40(6):596-605.
- Gaby AR. Dehydroepiandrosterone: biological effects and clinical significance. *Altern Med Rev* 1996;1(2):60-69.
- Gebre-Medhin G, Husebye ES, Mallmin H, et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. *Clin Endocrinol (Oxf)* 2000;52(6):775-780.
- Genazzani AD, Stomati M, Bernardi F, et al. Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids. *Fertil Steril* 2003;80(6):1495-1501.
- Gennari R, Alexander JW. Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. *Crit Care Med* 1997;25(7):1207-1214.
- Gordon GB, Bush TL, Helzlsouer KJ, et al. Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. *Cancer Res* 1990;50:3859-3862.
- Grottoli S, Maccagno B, Ramunni J, et al. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. *J Endocrinol Invest* 2002;25(5):420-425.
- Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst* 1998;90:1292-1299.
- Harle P, Pongratz G, Weidler C, et al. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. *Ann Rheum Dis* 2004;63(7):809-816.
- Hartkamp A, Geenen R, Godaert GL, et al. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus. *Arthritis Rheum* 2004;50(11):3591-3595.
- Hartzband PI, Van Herle AJ, Sorger L, et al. Assessment of hypothalamic-pituitary-adrenal (HPA) axis dysfunction: comparison of ACTH stimulation, insulin-hypoglycemia and metyrapone. *J Endocrinol Invest* 1988;11:769-776.
- Hautanen A, Manttari M, Manninen V, et al. Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. *Atherosclerosis* 1994;105:191-200.
- Heinonen PK, Koivula T, Pystynen P. Decreased serum level of dehydroepiandrosterone sulfate in postmenopausal women with ovarian cancer. *Gynecol Obstet Invest* 1987;23:271-274.
- Helzlsouer KJ, Alberg AJ, Gordon GB, et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. *JAMA* 1995;274:1926-1930.
- Helzlsouer KJ, Gordon GB, Alberg AJ, et al. Relationship of prediagnostic serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing premenopausal breast cancer. *Cancer Res* 1992;52:1-4.
- Hunt PJ, Gurnell EM, Huppert FA, et al. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. *J Clin Endocrinol Metab* 2000;85(12):4650-4656.
- Huppert FA, Van Niekerk JK. Dehydroepiandrosterone (DHEA) supplementation for cognitive function (Cochrane Review). *Cochrane Database* 2001;2:CD000304.
- Johannes CB, Stellato RK, Feldman HA, et al. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. *J Clin Epidemiol* 1999;52:95-103.
- Jones JA, Nguyen A, Strab M, et al. Use of DHEA in a patient with advanced prostate cancer: a case report and review. *Urology* 1997;50:784-788.
- Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. *J Clin Endocrinol Metab* 2003;88(7):3190-3195.
- Kim SS, Brody KH. Dehydroepiandrosterone replacement in Addison's disease. *Eur J Obstet Gynecol Reprod Biol* 2001;97(1):96-97.
- Krause W, Mueller U, Mazur A. Measurement of steroid levels in saliva in a population-based survey of lifestyle, medical conditions, marriage, sex life and hormone status in aging men: a feasibility study. *Aging Male* 2002;5(4):203-215.

Citations and Reference Literature: DHEA

- Kroboth PD, Amico JA, Stone RA, et al. Influence of DHEA administration on 24-hour cortisol concentrations. *J Clin Psychopharmacol* 2003;23(1):96-99.
- Labrie F, Belanger A, Cusan L, et al. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. *J Clin Endocrinol Metab* 1997;82(8):2403-2409.
- Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. *J Clin Endocrinol Metab* 1997;82(10):3498-3505.
- Le Bail JC, Lotfi H, Charles L, et al. Conversion of dehydroepiandrosterone sulfate at physiological plasma concentration into estrogens in MCF-7 cells. *Steroids* 2002;67(13-14):1057-1064.
- Loviselli A, Pisanu P, Cossu E, et al. Low levels of dehydroepiandrosterone sulfate in adult males with insulin-dependent diabetes mellitus. *Minerva Endocrinol* 1994;19:113-119.
- Mahesh VB, Greenblatt RB. The in vivo conversion of dehydroepiandrosterone and androstenedione to testosterone in the human. *Acta Endocrinologica* 1962;41:400-406.
- Mano T, Mori K, Sawai Y, et al. Accelerated conversion of dehydroepiandrosterone sulfate to estrogen in a patient with Crow-Fukase syndrome and diabetes mellitus. *Endocr Res* 1999;25(3-4):371-380.
- Marwah A, Marwah P, Lardy H. Ergosteroids VII: perchloric acid-induced transformations of 7-oxygenated steroids and their bio-analytical applications: a liquid chromatographic-mass spectrometric study. *Bioorg Chem* 2002;30(4):233-248.
- Marwah A, Marwah P, Lardy H. Ergosteroids VI: metabolism of dehydroepiandrosterone by rat liver in vitro: a liquid chromatographic-mass spectrometric study. *J Chromatogr B Analyt Technol Biomed Life Sci* 2002;767(2):285-299.
- Marwah P, Marwah A, Kneer N, et al. Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates. *Steroids* 2001;66(7):581-595.
- McIntosh MK, Berdanier CD. Influence of dehydroepiandrosterone (DHEA) on the thyroid hormone status of BHE/cdb rats. *J Nutr Biochem* 1992;3:194-199.
- Melchior CL, Ritzmann RF. Dehydroepiandrosterone enhances the hypnotic and hypothermic effects of ethanol and pentobarbital. *Pharmacol Biochem Behav* 1992;43:223-227.
- Meno-Tetang GM, Blum RA, Schwartz KE, et al. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. *J Clin Pharmacol* 2001;41(11):1195-1205.
- Meno-Tetang GM, Hon YY, Van Wart S, et al. Pharmacokinetic and pharmacodynamic interactions between dehydroepiandrosterone and prednisolone in the rat. *Drug Metabol Drug Interact* 1999;15(1):51-70.
- Merril CR, Harrington MG, Sunderland T. Reduced plasma dehydroepiandrosterone concentrations in HIV infection and Alzheimers disease. In: Kalimi M, Regelson W, eds. *The biological role of dehydroepiandrosterone*. New York: de Gruyter; 1990:101-105.
- Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. *Clin Endocrinol (Oxf)* 1998;49:421-432.
- Morales AJ, Nolan JJ, Nelson JC, et al. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. *J Clin Endocrinol Metab* 1994;78(6):1360-1367.
- Mortola JF, Yen SSC. The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. *J Clin Endocrinol Metab* 1990;71:696-704.
- Nestler JE, Whitfield JB, Williams TY, et al. Genetics of serum dehydroepiandrosterone sulfate and its relationship to insulin in a population-based cohort of twin subjects. *J Clin Endocrinol Metab* 2002;87(2):682-686.
- Nilsson T, Mellbring G, Damber JE. Relationships between tissue plasminogen activator, steroid hormones and deep vein thrombosis. *Acta Chir Scand* 1985;151(6):515-519.
- Oelkers W. Dehydroepiandrosterone for adrenal insufficiency. *N Engl J Med* 1999;341(14):1073-1074.
- Orner GA, Mathews C, Hendricks JD, et al. Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the absence of peroxisome proliferation in rainbow trout. *Carcinogenesis* 1995;16:2893-2898.
- Osawa E, Nakajima A, Yoshida S, et al. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone (DHEA). *Life Sci* 2002;70(22):2623-2630.
- Parasrampur J, Schwartz K, Petesch R. Quality control of dehydroepiandrosterone dietary supplement products. *JAMA* 1998;280:1565. (Letter)
- Pelissier MA, Trap C, Malewiak MI, et al. Antioxidant effects of dehydroepiandrosterone and 7alpha-hydroxy-dehydroepiandrosterone in the rat colon, intestine and liver. *Steroids* 2004;69(2):137-144.
- Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. *Arthritis Rheum* 2004;50(9):2858-2868.

Citations and Reference Literature: DHEA

- Piketty C, Jayle D, Lepage A, et al. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. *Clin Endocrinol* 2001;55(3):325-330.
- Porsova-Dutoit I, Sulcova J, Starka L. Do DHEA/DHEAS play a protective role in coronary heart disease? *Physiol Res* 2000;49(Suppl 1):S43-556. (Review)
- Potosky AL, Reeve BB, Clegg LX, et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. *J Natl Cancer Inst* 2002;94(6):430-437.
- Ram PA, Waxman DJ. Dehydroepiandrosterone 3 beta-sulphate is an endogenous activator of the peroxisome-proliferation pathway: induction of cytochrome P-450 4A and acyl-CoA oxidase mRNAs in primary rat hepatocyte culture and inhibitory effects of Ca(2+)-channel blockers. *Biochem J* 1994;301 (Pt 3):753-758.
- Regelson W, Loria S, Kalimi M. Hormonal intervention: buffer hormones or state dependency: the role of dehydroepiandrosterone (DHEA), thyroid hormone, estrogen and hypophysectomy in aging. *Ann N Y Acad Sci* 1988;521:260-273.
- Riedel M, Wiese A, Schurmeyer TH, et al. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. *Exp Clin Endocrinol* 1993;101(2):106-111.
- Reiter WJ, Schatzl G, Mark I, et al. Dehydroepiandrosterone in the treatment of erectile dysfunction in patients with different organic etiologies. *Urol Res* 2001;29(4):278-281.
- Riedel M, Wiese A, Schurmeyer TH, et al. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. *Exp Clin Endocrinol* 1993;101(2):106-111.
- Rosen T, Wiren L, Wilhelmssen L, et al. Decreased psychological well-being in adult patients with growth hormone deficiency. *Clin Endocrinol (Oxf)* 1994;40(1):111-116.
- Salek FS, Bigos KL, Kroboth PD. The influence of hormones and pharmaceutical agents on DHEA and DHEA-S concentrations: a review of clinical studies. *J Clin Pharmacol* 2002;42(3):247-266.
- Shunkert H, Hense H-W, Andus T, et al. Relation between dehydroepiandrosterone sulfate and blood pressure levels in a population-based sample. *Am J Hypertens* 1999;12:1140-1143.
- Scott LV, Salahuddin F, Cooney J, et al. Differences in adrenal steroid profile in chronic fatigue syndrome, in depression and in health. *J Affect Disord* 1999;54(1-2):129-137.
- Simile M, Pascale RM, De Miglio MR, et al. Inhibition by dehydroepiandrosterone of growth and progression of persistent liver nodules in experimental rat liver carcinogenesis. *Int J Cancer* 1995;62: 210-215.
- Schneider HP. Androgens and antiandrogens. *Ann N Y Acad Sci* 2003;997:292-306.
- Stomati M, Monteleone P, Casarosa E, et al. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. *Gynecol Endocrinol* 2000;14(5):342-363.
- Stomati M, Rubino S, Spinetti A, et al. Endocrine, neuroendocrine and behavioral effects of oral dehydroepiandrosterone sulfate supplementation in postmenopausal women. *Gynecol Endocrinol* 1999;13(1):15-25.
- Straub RH, Weidler C, Demmel B, et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheum Dis* 2004;63(8):961-968.
- Sullivan DA, Belanger A, Cermak JM, et al. Are women with Sjogren's syndrome androgen-deficient? *J Rheumatol* 2003;30(11): 2413-2419.
- Sun Y, Mao M, Sun L, et al. Treatment of osteoporosis in men using dehydroepiandrosterone sulfate. *Chin Med J (Engl)* 2002;115(3): 402-404.
- Suzuki M, Kanazawa A, Hasegawa M, et al. A close association between insulin resistance and dehydroepiandrosterone sulfate in subjects with essential hypertension. *Endocr J* 1999;46:521-528.
- Suzuki M, Wright LS, Marwah P, et al. Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. *Proc Natl Acad Sci U S A* 2004;101(9):3202-3207.
- Svacina S, Sonka J, Haas T. Dehydroepiandrosterone and insulinaemia. *Sb Lek* 1995;96(4):303-306.
- Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. *Circulation* 1998;98(21):2241-2247.
- van Vollenhoven RF, Morabito LM, Engleman EG, et al. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. *J Rheumatol* 1998;25:285-289.
- Vetrotsky DT, Aliabadi Z. The andropause debate: aging process or disease state? *Clinician Rev* 2002;12(3):78-85.
- Villareal DT, Holloszy JO. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. *JAMA* 2004;292:2243-2248.
- Villareal DT, Holloszy JO, Kohrt WM. Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. *Clin Endocrinol (Oxf)* 2000;53(5):561-568.

Citations and Reference Literature: DHEA

- Wolf OT, Neumann O, Hellhammer DH, et al. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. *J Clin Endocrinol Metab* 1997;82(7):2363-2367.
- Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. *Am J Psychiatry* 1999;156(4):646-649.
- Yanase T, Suzuki S, Goto K, et al. Aromatase in bone: roles of vitamin D(3) and androgens. *J Steroid Biochem Mol Biol* 2003;86(3-5):393-397.
- Yen SS, Morales AJ, Khorram O. Replacement of DHEA in aging men and women: potential remedial effects. *Ann N Y Acad Sci* 1995;774:128-142.
- Yoshida S, Honda A, Matsuzaki Y, et al. Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines. *Steroids* 2003;68(1):73-83.
- Zeleniuch-Jacquotte A, Bruning PF, Bonfrer JM, et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. *Am J Epidemiol* 1997;145:1030-1038.
- Zietz B, Reber T, Oertel M, et al. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus: II: dissociation between androstenedione, cortisol, or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor. *J Rheumatol* 2000;27(4):911-918.
- Zofkova I, Zajickova K, Hill M, et al. Apolipoprotein E gene determines serum testosterone and dehydroepiandrosterone levels in postmenopausal women. *Eur J Endocrinol* 2002;147(4):503-506.
- Zumoff B, Levin J, Rosenfeld RS, et al. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. *Cancer Res* 1981;41:3360-3363.